Posts Tagged ‘pancreatic cancer’

New funding for a dire need: Pancreas cancer early detection

With a $250,000 award from the Pancreatic Cancer Action Network, researchers will seek to validate biomarkers able to detect pancreas cancer months or years before patients experience overt symptoms of the disease.   Pancreatic ductal adenocarcinoma is the deadliest of the major cancer types, with a five-year survival rate of less than 10 percent. Unlike the other major causes of cancer mortality, pancreatic cancer is increasing in both incidence and number of deaths each year. Principal investigator Brett Sheppard, … Read More

New insight into the anti-cancer effect of aspirin

For reasons that remain uncertain, people who take aspirin on a regular basis have a reduced risk of colorectal cancer and certain other malignancies. Now researchers have identified a previously unknown way that aspirin could achieve this result: “The benefit of aspirin may be due to its effect on blood cells called platelets rather than acting directly on tumor cells,” says Owen McCarty, Ph.D., a professor in the Department of Biomedical Engineering at Oregon Health … Read More

Marquam Hill Lecture: Confronting the unexpected rise of pancreas cancer

Unlike the other major causes of cancer mortality, pancreatic cancer is increasing in both incidence and number of deaths each year. Despite improvements in early detection and therapy that have greatly improved outcomes in other cancers, the five-year survival rate remains less than 8 percent for people diagnosed with pancreatic cancer. It’s on a course to become the second largest cause of cancer death within five to ten years – ahead of colorectal, breast, prostate … Read More

Wanted: Patients’ perspectives on cancer research

Five years ago, Betty Booher’s husband was diagnosed with primary cancers in the colon and the pancreas and died at age 57. In the aftermath, she says, “It was important to me to find a way to join the fight against cancer.” Booher found a way by becoming a scientific research advocate at the OHSU Knight Cancer Institute.

Finding lessons in a failed pancreatic cancer clinical trial

Nearly a third of people diagnosed with pancreatic adenocarcinoma have locally advanced tumors that cannot be removed by surgery. A longstanding and critical question for these patients is whether adding radiation to chemotherapy provides any benefit. Alas, the answer appears to be no, according to the recently completed LAP07 study, which was stopped early when an interim analysis failed to demonstrate a benefit in overall survival. While disappointing, the finding fits with the emerging view that pancreatic cancer is … Read More

Advancing a potential blood test for pancreatic cancer

Immunovia’s “IMMray” technology uses an antibody microarray to detect the protein signature of pancreatic cancer in blood samples.   The Swedish biotech firm Immunovia reached another milestone with the OHSU Knight Cancer Institute in developing a blood test to speed the diagnosis of pancreatic cancer. Immunovia’s antibody microarray correctly classified 96 percent of patients with stage I or II pancreatic ductal adenocarcinoma in a retrospective study using samples from North American pancreatic cancer patients. These results match … Read More

Immune signature in blood could enable earlier detection of pancreatic cancer

Less than one in ten cases of pancreatic cancer in the U.S. are diagnosed at the local stage. And the relative survival rate — around 6 percent at five years — is by far the worst among major cancers. The OHSU Knight Cancer Institute and the Swedish biotech firm Immunovia AG recently announced a collaboration to develop blood tests that could enable earlier diagnosis of pancreatic cancer.

Targeting leukemia with drug combinations

Targeting leukemia with drug combinations

Cancer researchers have devised a way to rapidly screen combinations of drugs to identify pairs of agents most likely to work synergistically against some of the most difficult to treat forms of leukemia.